MiddleBrook Pharmaceuticals, Inc
MiddleBrook Pharmaceuticals, Inc. is a publicly traded pharmaceutical company (NASDAQ: MBRK) offering anti-infective products and antibiotics, headquartered in West Lake Hills, Texas with 251-500 employees.
- Company typePrivate
- Founded2000
- HeadquartersWest Lake Hills, United States
- Headcount251–500
- GTM typeB2B
- OfferingHardware or Manufacturing
What MiddleBrook Pharmaceuticals, Inc does
MiddleBrook Pharmaceuticals, Inc. is a publicly traded pharmaceutical company listed on NASDAQ under ticker MBRK, founded in 2000 and headquartered in West Lake Hills, Texas. Per the firmographic data, the company is positioned in the anti-infective product and antibiotics therapeutic category and operates with a stated headcount of 251-500 employees.
The available dataset is materially thin on operational specifics. The corporate website (middlebrookpharma.com) is currently listed for sale on the Atom domain marketplace rather than hosting an active company site, and no product portfolio, technology platform, management team, partnerships, certifications, regulatory actions, or M&A history is documented in the provided data. There are no disclosed products, pricing, distribution channels, marketing channels, or named customers, so the business model and revenue mechanics cannot be characterized from the input.
The company has raised approximately $131 million across three funding rounds between November 2007 and July 2008. Equity Group Investments led a $100 million round in July 2008, with prior rounds funded by HealthCare Ventures and Rho Ventures ($21M, February 2008) and Deerfield ($10M, November 2007). The absence of any documented post-2008 capital, product, or operational activity, combined with the dormant website, raises material uncertainty about the company's current operating status and renders most investment-relevant attributes unverifiable from the available evidence.
MiddleBrook Pharmaceuticals, Inc firmographics
Firmographics- Name
- MiddleBrook Pharmaceuticals, Inc
- Website
- https://middlebrookpharma.com
- Company type
- Private
- Founded year
- 2000
- Headcount range
- 251–500 employees
- Short description
- MiddleBrook Pharmaceuticals, Inc. is a publicly traded pharmaceutical company (NASDAQ: MBRK) offering anti-infective products and antibiotics, headquartered in West Lake Hills, Texas with 251-500 employees.
- Ownership category
- akta.pro rank
MiddleBrook Pharmaceuticals, Inc industry classification
Industry- Product category
- Anti-infective Pharmaceuticals
- NAICS
- Pharmaceutical Preparation Manufacturing (325412)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Infectious Disease Specialty Pharmaceuticals (Non-vaccine) (HLAIACAM)
Keywords
Where MiddleBrook Pharmaceuticals, Inc is headquartered
LocationHeadquarters
- HQ city
- West Lake Hills
- HQ country
- United States
- HQ region
- North America
Markets served
MiddleBrook Pharmaceuticals, Inc business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales
MiddleBrook Pharmaceuticals, Inc product offering
Product offeringCore offering
MiddleBrook Pharmaceuticals develops, manufactures, and commercializes anti-infective pharmaceutical products, primarily antibiotics, intended for the treatment of bacterial infections. The offerings are targeted at healthcare providers and patients requiring branded antibiotic therapies for infectious diseases.
Product overview
MiddleBrookPharma.com is a premium domain name listed for sale on Atom Marketplace. It is not an existing product or service offering from an operational company; rather, it represents a domain asset potentially suitable for healthcare, biotech, telehealth, or pharmaceutical ventures. No active product portfolio, named offerings, or technology platform exists for this domain listing.
Differentiator
Problem solved
Functional benefit
Companies that use MiddleBrook Pharmaceuticals, Inc
Customer profileIdeal customer profiles1 record
MiddleBrook Pharmaceuticals, Inc technology and API
TechnologyAPI detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
MiddleBrook Pharmaceuticals, Inc partnerships and signals
Strategic signalRecent moves3 records
Expansion highlights1 record
MiddleBrook Pharmaceuticals, Inc competitors and assessment
Company assessmentDirect peers
- Melinta Therapeutics: Anti-infectives pure-play commercializing antibiotics including Baxdela and Orbactiv. Directly comparable to MiddleBrook as a fellow antibiotics-focused company serving hospital and infectious-disease prescribers in the US.
- Paratek Pharmaceuticals: Commercial-stage anti-infective company (Nuzyra/seysara). Comparable as a focused antibiotics commercial-stage company with similar regulatory-approved portfolio positioning and stewardship constraints.
- Spero Therapeutics: Clinical-stage anti-infectives company developing antibiotics for multidrug-resistant infections. Comparable niche focus on novel-mechanism antibiotics addressing AMR-driven demand, similar regulatory and commercial pathway to an anti-infective specialist.
- Tetraphase Pharmaceuticals: Anti-infective company known for Xerava (eravacycline) — a comparable antibiotics specialist whose commercialization challenges illustrate the category economics any anti-infective specialist faces.
- Iterum Therapeutics: Anti-infective company developing oral and IV antibiotics for resistant pathogens. Directly comparable small-cap, antibiotics-focused profile targeting similar hospital/institutional prescribers.
- Nabriva Therapeutics: Anti-infectives company developing antibiotics (e.g., lefamulin/Xenleta) for community and hospital settings. Directly comparable antibiotics pure-play with similar commercial-stage execution challenges.
Others
- Achaogen: Historical anti-infective company (plazomicin/Zemdri) that filed for bankruptcy post-launch. Included as a peer primarily for relevant warning about commercial outcomes in the antibiotics category rather than as a current competitor.
Emerging players
- Cidara Therapeutics: Anti-infective company developing novel antibacterials and antivirals. Comparable as a specialist addressing infectious-disease treatment, with adjacent product-class exposure (antibacterials). Useful proxy for category economics.
- VenatoRx Pharmaceuticals: Clinical-stage anti-infective company developing novel antibiotics targeting resistant infections. Comparable focus area (anti-infectives) and AMR-driven opportunity, though earlier stage and narrower in commercialization.
Regional players
- Motif Bio: UK-listed antibiotics developer (iclaprim). Comparable antibiotics-focused profile with comparable stewardship and pricing dynamics, though geographically distinct (UK/Europe vs US anchor).
Market position
Strengths3 records
Weaknesses3 records
Competitive moat2 records
Key risks5 records
Key highlights4 records
Customer concentration
MiddleBrook Pharmaceuticals, Inc social profiles
Digital presenceMiddleBrook Pharmaceuticals, Inc financial estimates
Financial estimateRevenue estimate
Valuation estimate
MiddleBrook Pharmaceuticals, Inc leadership team
Management profileNumber of profiles
MiddleBrook Pharmaceuticals, Inc funding detail
Funding detailFunding overview
Funding rounds3 records
Investors4 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
MiddleBrook Pharmaceuticals, Inc M&A and investment
M&A and investmentM&A
Investments1 record
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about MiddleBrook Pharmaceuticals, Inc
What does MiddleBrook Pharmaceuticals, Inc do?
MiddleBrook Pharmaceuticals develops, manufactures, and commercializes anti-infective pharmaceutical products, primarily antibiotics, intended for the treatment of bacterial infections. The offerings are targeted at healthcare providers and patients requiring branded antibiotic therapies for infectious diseases.
When was MiddleBrook Pharmaceuticals, Inc founded?
MiddleBrook Pharmaceuticals, Inc was founded in 2000. It employs 251 to 500 people.
Where is MiddleBrook Pharmaceuticals, Inc based?
MiddleBrook Pharmaceuticals, Inc is headquartered in West Lake Hills, United States, in the North America region.
Who are MiddleBrook Pharmaceuticals, Inc's main competitors?
Direct peers on record are Melinta Therapeutics, Paratek Pharmaceuticals, Spero Therapeutics, Tetraphase Pharmaceuticals, Iterum Therapeutics and Nabriva Therapeutics. Achaogen is listed as an others. Emerging players are Cidara Therapeutics and VenatoRx Pharmaceuticals. Motif Bio is listed as a regional player.
Does MiddleBrook Pharmaceuticals, Inc have an API?
No public API is recorded for MiddleBrook Pharmaceuticals, Inc.
What industry is MiddleBrook Pharmaceuticals, Inc in?
MiddleBrook Pharmaceuticals, Inc's product category is Anti-infective Pharmaceuticals. Its primary akta.pro industry code is HLAIACAM, Infectious Disease Specialty Pharmaceuticals (Non-vaccine). Its NAICS code is 325412 and its SIC code is 2834.